ArticleScientific reports2017
Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Role of the CB2 Cannabinoid Receptor in the Regulation of Food Intake: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.International journal of molecular sciences · 2020Pooled it
- The effect of a synthetic cannabinoid agonist (nabilone) on unimodal tactile illusion correlates with a psychometric scores in healthy volunteers.Scientific reports · 2025Trial
- Review
- PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders.Neuroscience bulletin · 2026Review
- Distinct contributions of mu opioid and CB2 cannabinoid receptors to neuroimmune and behavioral responses.Advances in drug and alcohol research · 2026Article
- Genetic Tools in Rodents to Study Cannabinoid Functions.Current topics in behavioral neurosciences · 2026Review
- Acute or Chronic β-Caryophyllene Systemic Administration in Healthy Adult Male Mice Does Not Modulate Anxiety-Like Extinction Behavior Induced by Subsequent Re-Exposure to 3D Maze.Fundamental & clinical pharmacology · 2025Article
- The Administration of Cannabinoid Receptor 2 Agonist Decreases Binge-like Intake of Palatable Food in Mice.International journal of molecular sciences · 2025Article
- Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters.Frontiers in pharmacology · 2025Article
- The effect of cannabinoid type Ⅱ receptor on the excitability of substantia nigra dopaminergic neurons.Frontiers in pharmacology · 2025Article
- CB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions.Journal of neuroinflammation · 2024Article
- JWH-182: a safe and effective synthetic cannabinoid for chemotherapy-induced neuropathic pain in preclinical models.Scientific reports · 2024Article
- Cannabinoid CB2 receptors and hypersensitivity to methamphetamine: Vulnerability to schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry · 2024Article
- Anxiety Modulation by Cannabinoids-The Role of Stress Responses and Coping.International journal of molecular sciences · 2023Review
- Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy.Biomolecules · 2023Review
- Acute Toxicity and Pharmacokinetic Profile of an EU-GMP-CertifiedPharmaceuticals (Basel, Switzerland) · 2023Article
- The Polypharmacological Effects of Cannabidiol.Molecules (Basel, Switzerland) · 2023Review
- Update on the controversial identity of cells expressing cnr2 gene in the nervous system.CNS neuroscience & therapeutics · 2023Review
- Research progress on the cannabinoid type-2 receptor and Parkinson's disease.Frontiers in aging neuroscience · 2023Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
Cannabinoid CB2 receptors (CB2Rs) are expressed in mouse brain dopamine (DA) neurons and are involved in several DA-related disorders. However, the cell type-specific mechanisms are unclear since the CB2R gene knockout mice are constitutive gene knockout. Therefore, we generated Cnr2-floxed mice that were crossed with DAT-Cre mice, in which Cre- recombinase expression is under dopamine transporter gene (DAT) promoter control to ablate Cnr2 gene in midbrain DA neurons of DAT-Cnr2 conditional knockout (cKO) mice. Using a novel sensitive RNAscope in situ hybridization, we detected CB2R mRNA expression in VTA DA neurons in wildtype and DAT-Cnr2 cKO heterozygous but not in the homozygous DAT-Cnr2 cKO mice. Here we report that the deletion of CB2Rs in dopamine neurons enhances motor activities, modulates anxiety and depression-like behaviors and reduces the rewarding properties of alcohol. Our data reveals that CB2Rs are involved in the tetrad assay induced by cannabinoids which had been associated with CB1R agonism. GWAS studies indicates that the CNR2 gene is associated with Parkinson's disease and substance use disorders. These results suggest that CB2Rs in dopaminergic neurons may play important roles in the modulation of psychomotor behaviors, anxiety, depression, and pain sensation and in the rewarding effects of alcohol and cocaine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.